An up-to-date review of rutin and its biological and pharmacological activities
It mediates trophoblast invasion into the uterine wall and placental vascularization
HU-6 is a CMA, administered orally once a day, currently under development for the treatment of obesity and related complications, such as T2DM, MASH, severe hypertriglyceridemia, and heart failure with preserved ejection fraction (HFpEF) ( The HuMAIN study, a phase 2a trial examining HU-6 in subjects with HFpEF shows a mean weight loss of 3.1kg compared to 0.2 kg for the placebo group at three months ( 7 Melanocortin 4 receptor agonists 7.1 Setmelanotide Setmelanotide is a melanocortin-4 receptor (MC4R) agonist that is administered subcutaneously once a day ( It is being investigated for treatment of various heterozygous mutations in LepR, POMC, or PCSK1 genes, and homozygous or heterozygous mutations in the steroid receptor coactivator-1 (SRC1) or SH2B adapter protein 1 (SH2B1) genes ( Setmelanotide is currently being studied for treatment of acquired hypothalamic obesity (HO), a condition occurring after injury to the relevant satiety centers, also characterized by hyperphagia and rapid weight gain
Peptide Stacks Under $200/Month 4 complete peptide protocols under $200/month fat loss, healing, anti-aging, sleep
Impey, et al
